STOCK TITAN

ElectroCore Inc - ECOR STOCK NEWS

Welcome to our dedicated news page for ElectroCore (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on ElectroCore.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ElectroCore's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ElectroCore's position in the market.

Rhea-AI Summary
Clinical trial data presented at the American College of Gastroenterology Annual Meeting shows that nVNS can reduce the use of rescue medications for nausea due to Gastroparesis or Functional Dyspepsia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
none
-
Rhea-AI Summary
electroCore's gammaCore therapy to be listed in the UK's NHS Supply Chain catalogue for an additional two years
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
-
Rhea-AI Summary
electroCore announces issuance of U.S. patent for nVNS treatment protocol
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
Rhea-AI Summary
electroCore announces positive results from nVNS clinical trials for headache and stroke treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.11%
Tags
none
-
Rhea-AI Summary
electroCore, Inc. to report Q3 2023 financial results on November 8, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
earnings
-
Rhea-AI Summary
electroCore CEO to participate in Lytham Partners Fall 2023 Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
conferences
Rhea-AI Summary
electroCore, Inc. announces two peer-reviewed publications supporting the use of gammaCore in patients with PTSD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
none
-
Rhea-AI Summary
electroCore, Inc. has been issued a patent related to non-invasive nerve stimulation with mobile devices, strengthening their position in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.98%
Tags
none
-
Rhea-AI Summary
electroCore CEO to present at LD Micro Main Event XVI Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
conferences
Rhea-AI Summary
electroCore, Inc. CEO to present at iAccess Alpha's virtual conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
ElectroCore Inc

Nasdaq:ECOR

ECOR Rankings

ECOR Stock Data

35.24M
4.17M
27.3%
15.98%
0.27%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
United States
Rockaway

About ECOR

electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.